Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Molecular virology of hepatitis B virus for clinicians.

Literature DB >> 17981225

Molecular virology of hepatitis B virus for clinicians.

Timothy M Block¹, Haitao Guo, Ju-Tao Guo.

Abstract

This article reviews the molecular biology of the hepatitis B virus in an effort to explain its natural history from a molecular perspective. The life cycle of the virus, with special attention to virus replication, polypeptide production, and morphogenesis, is described. The way in which these steps may influence the natural history of viral pathogenesis, as well as the effectiveness of interventions, receives special consideration.

Entities: Species

Mesh：

Substances：

Year: 2007 PMID： 17981225 PMCID： PMC2144742 DOI： 10.1016/j.cld.2007.08.002

Source DB: PubMed Journal: Clin Liver Dis ISSN： 1089-3261 Impact factor: 6.126

97 in total

1. Duck hepatitis B virus virion secretion requires a double-stranded DNA genome.

Authors: David Perlman; Jianming Hu
Journal: J Virol Date: 2003-02 Impact factor: 5.103

2. Infection of a human hepatoma cell line by hepatitis B virus.

Authors: Philippe Gripon; Sylvie Rumin; Stephan Urban; Jacques Le Seyec; Denise Glaise; Isabelle Cannie; Claire Guyomard; Josette Lucas; Christian Trepo; Christiane Guguen-Guillouzo
Journal: Proc Natl Acad Sci U S A Date: 2002-11-13 Impact factor: 11.205

3. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.

Authors: Ching-Lung Lai; Mohamed Rosmawati; Judy Lao; Hans Van Vlierberghe; Frank H Anderson; Neal Thomas; Deborah Dehertogh
Journal: Gastroenterology Date: 2002-12 Impact factor: 22.682

4. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.

Authors: Harry L A Janssen; Monika van Zonneveld; Hakan Senturk; Stefan Zeuzem; Ulus S Akarca; Yilmaz Cakaloglu; Christopher Simon; Thomas M K So; Guido Gerken; Robert A de Man; Hubert G M Niesters; Pieter Zondervan; Bettina Hansen; Solko W Schalm
Journal: Lancet Date: 2005 Jan 8-14 Impact factor: 79.321

5. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids.

Authors: Karl Deres; Claus H Schröder; Arnold Paessens; Siegfried Goldmann; Hans Jörg Hacker; Olaf Weber; Thomas Krämer; Ulrich Niewöhner; Ulrich Pleiss; Jürgen Stoltefuss; Erwin Graef; Diana Koletzki; Ralf N A Masantschek; Anja Reimann; Rainer Jaeger; Rainer Gross; Bernhard Beckermann; Karl-Heinz Schlemmer; Dieter Haebich; Helga Rübsamen-Waigmann
Journal: Science Date: 2003-02-07 Impact factor: 47.728

Review 6. Regulatory elements of hepatitis B virus transcription.

Authors: Naazneen Moolla; Michael Kew; Patrick Arbuthnot
Journal: J Viral Hepat Date: 2002-09 Impact factor: 3.728

Review 7. Molecular viral oncology of hepatocellular carcinoma.

Authors: Timothy M Block; Anand S Mehta; Claus J Fimmel; Robert Jordan
Journal: Oncogene Date: 2003-08-11 Impact factor: 9.867

8. Genomic analysis of the host response to hepatitis C virus infection.

Authors: Andrew I Su; John P Pezacki; Lisa Wodicka; Amy D Brideau; Lubica Supekova; Robert Thimme; Stefan Wieland; Jens Bukh; Robert H Purcell; Peter G Schultz; Francis V Chisari
Journal: Proc Natl Acad Sci U S A Date: 2002-11-19 Impact factor: 11.205

Review 9. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus.

Authors: Joseph Torresi
Journal: J Clin Virol Date: 2002-08 Impact factor: 3.168

10. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model.

Authors: O Weber; K-H Schlemmer; E Hartmann; Ina Hagelschuer; A Paessens; E Graef; K Deres; S Goldmann; U Niewoehner; J Stoltefuss; D Haebich; H Ruebsamen-Waigmann; Stefan Wohlfeil
Journal: Antiviral Res Date: 2002-05 Impact factor: 5.970

69 in total

1. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation.

Authors: Dawei Cai; Courtney Mills; Wenquan Yu; Ran Yan; Carol E Aldrich; Jeffry R Saputelli; William S Mason; Xiaodong Xu; Ju-Tao Guo; Timothy M Block; Andrea Cuconati; Haitao Guo
Journal: Antimicrob Agents Chemother Date: 2012-05-29 Impact factor: 5.191

Review 2. Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics.

Authors: Ju-Tao Guo; Haitao Guo
Journal: Antiviral Res Date: 2015-08-10 Impact factor: 5.970

Review 3. Drug delivery systems and liver targeting for the improved pharmacotherapy of the hepatitis B virus (HBV) infection.

Authors: María L Cuestas; Verónica L Mathet; José R Oubiña; Alejandro Sosnik
Journal: Pharm Res Date: 2010-03-24 Impact factor: 4.200

4. Genotyping of hepatitis B virus isolates from Lahaul and Spiti district in Himachal Pradesh, India.

Authors: Brij Sharma; Harshita Katiyar; Deepesh Barall; Neetu Sharma; Shikha Agnihotry; Amit Goel; Rakesh Aggarwal
Journal: Indian J Gastroenterol Date: 2018-06-01

Review 5. Host functions used by hepatitis B virus to complete its life cycle: Implications for developing host-targeting agents to treat chronic hepatitis B.

Authors: Bidisha Mitra; Roshan J Thapa; Haitao Guo; Timothy M Block
Journal: Antiviral Res Date: 2018-08-24 Impact factor: 5.970